TP53 mutation predicts sensitivity to adjuvant gemcitabine in pancreatic cancer: Results from the CONKO-001 study

Subjects

Subjects :

0301 basic medicine
Oncology
medicine.medical_specialty
business.industry
medicine.medical_treatment
Hematology
medicine.disease
Gemcitabine
03 medical and health sciences
030104 developmental biology
0302 clinical medicine
030220 oncology & carcinogenesis
Internal medicine
Pancreatic cancer
Mutation (genetic algorithm)
medicine
Sensitivity (control systems)
business
Adjuvant
medicine.drug

Details

ISSN :

09237534

Volume :

28

Database :

OpenAIRE

Journal :

Annals of Oncology

Accession number :

edsair.doi...........cf2fd77395b983ab3d8fa3b5604ebd92

Full Text :

https://doi.org/10.1093/annonc/mdx369.120